McKesson Co. (NYSE:MCK) Shares Sold by Trilogy Capital Inc.

Trilogy Capital Inc. lessened its stake in McKesson Co. (NYSE:MCK) by 2.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,019 shares of the company’s stock after selling 21 shares during the period. Trilogy Capital Inc.’s holdings in McKesson were worth $581,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Wolff Wiese Magana LLC increased its position in McKesson by 742.9% in the 3rd quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock valued at $29,000 after acquiring an additional 52 shares during the period. MidAtlantic Capital Management Inc. acquired a new position in McKesson during the 3rd quarter worth approximately $29,000. RPg Family Wealth Advisory LLC acquired a new position in McKesson during the 3rd quarter worth approximately $31,000. Synergy Asset Management LLC acquired a new position in McKesson during the 4th quarter worth approximately $32,000. Finally, Crews Bank & Trust acquired a new position in McKesson during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on MCK. Wells Fargo & Company boosted their target price on McKesson from $535.00 to $641.00 and gave the stock an “equal weight” rating in a research report on Friday, December 13th. Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Morgan Stanley boosted their target price on McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Evercore ISI boosted their target price on McKesson from $650.00 to $675.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Mizuho initiated coverage on McKesson in a research note on Wednesday, December 4th. They set a “neutral” rating and a $630.00 price target on the stock. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, McKesson presently has a consensus rating of “Buy” and a consensus price target of $645.79.

McKesson Stock Performance

MCK stock opened at $598.85 on Friday. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $637.51. The stock’s 50 day moving average price is $589.61 and its 200 day moving average price is $562.56. The firm has a market cap of $76.02 billion, a P/E ratio of 31.01, a PEG ratio of 1.29 and a beta of 0.52.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. On average, research analysts predict that McKesson Co. will post 32.72 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be issued a $0.71 dividend. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.47%. McKesson’s dividend payout ratio (DPR) is presently 14.71%.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $602.81, for a total transaction of $349,026.99. Following the completion of the sale, the executive vice president now directly owns 1,443 shares in the company, valued at $869,854.83. This represents a 28.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.11% of the stock is currently owned by insiders.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.